Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Oct 7 · inside the Ichimoku cloud · RSI 40 · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $177.1K | 0.00% | 11.30K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BBNX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Hopman MarkOfficer | Sale at price 18.96 per share. | 370 | $7.01K |
| Sep 21, 2026 | Jones ChristyDirector | Sale at price 23.00 per share. | 6.4K | $147.89K |
| Sep 15, 2026 | Hopman MarkOfficer | Sale at price 20.13 per share. | 30.8K | $619.64K |
| Sep 15, 2026 | Mensinger MikeOfficer | Sale at price 22.00 per share. | 2.6K | $58.30K |
| Sep 13, 2026 | Hopman MarkOfficer | Sale at price 15.52 per share. | 775 | $12.03K |
| Sep 8, 2026 | Hopman MarkOfficer | Sale at price 18.46 per share. | 36.9K | $680.72K |
| Sep 2, 2026 | Saint SeanChief Executive Officer | Sale at price 20.08 per share. | 5.6K | $113.26K |
| Sep 1, 2026 | Saint SeanChief Executive Officer | Sale at price 19.11 per share. | 16.9K | $322.38K |
| Sep 1, 2026 | Feider StephenChief Financial Officer | Sale at price 19.11 per share. | 6.7K | $127.58K |
| Sep 1, 2026 | Hopman MarkOfficer | Sale at price 19.11 per share. | 5.3K | $101.81K |
| Sep 1, 2026 | Mensinger MikeOfficer | Sale at price 19.11 per share. | 4.4K | $83.62K |
| Sep 1, 2026 | Russell Steven JonOfficer | Sale at price 19.11 per share. | 4.2K | $80.68K |
| Jun 28, 2026 | Feider StephenChief Financial Officer | Sale at price 17.03 - 17.05 per share. | 10K | $170.39K |
| Jun 28, 2026 | Feider StephenChief Financial Officer | Conversion of Exercise of derivative security at price 5.10 per share. | 9.9K | $50.38K |
| Jun 28, 2026 | Feider StephenChief Financial Officer | Sale at price 17.03 - 17.05 per share. | 10K | $170.39K |
| Jun 28, 2026 | Feider StephenChief Financial Officer | Conversion of Exercise of derivative security at price 5.10 per share. | 10K | $51.00K |
| Jun 23, 2026 | Hopman MarkOfficer | Sale at price 15.01 per share. | 1.3K | $18.88K |
| Jun 23, 2026 | Jones ChristyDirector | Sale at price 15.00 per share. | 1.4K | $21.09K |
| Jun 3, 2026 | Hopman MarkOfficer | Sale at price 12.31 per share. | 275 | $3.38K |
| Jun 3, 2026 | Jones ChristyDirector | Sale at price 14.00 per share. | 2.8K | $39.35K |
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
Buy / hold / sell counts